Zobrazeno 1 - 10
of 193
pro vyhledávání: '"Andrew R Clamp"'
Autor:
Robert D Morgan, Andrew R Clamp, Jurjees Hasan, Gordon C Jayson, Sofia Stamatopoulou, Nerissa Mescallado, Geoff Saunders, Richard Welch, Claire Mitchell
Publikováno v:
ESMO Open, Vol 4, Iss 2 (2019)
Background Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection.Aim We
Externí odkaz:
https://doaj.org/article/d74e555a1ecd40a1a4eaec8366b7b3f3
Autor:
Robert D. Morgan, George J. Burghel, Helene Schlecht, Andrew R. Clamp, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Joseph Shaw, Sudha Desai, Gordon C. Jayson, Emma R. Woodward, D. Gareth R. Evans
Publikováno v:
Cancers, Vol 16, Iss 1, p 177 (2023)
Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect al
Externí odkaz:
https://doaj.org/article/3122f59188784a6ab441ba4e0329ec9f
Autor:
Robert D. Morgan, George J. Burghel, Nicola Flaum, Michael Bulman, Philip Smith, Andrew R. Clamp, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Emma R. Woodward, Fiona Lalloo, Emma J. Crosbie, Richard J. Edmondson, Helene Schlecht, Gordon C. Jayson, D. Gareth R. Evans
Publikováno v:
Cancers, Vol 15, Iss 3, p 730 (2023)
Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour BRCA1/2 variants. The value of germline BRCA1/2 testing in women diagnosed aged ≥80 is questionable. We performe
Externí odkaz:
https://doaj.org/article/226d8028d5794a148682355578cb1be9
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events. Often, these types of safety data are collected as two discrete data sets, wher
Externí odkaz:
https://doaj.org/article/94d37ab855b24cdf9c9c03a64e5de89c
Autor:
Robert D. Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price, George J. Burghel, W. David J. Ryder, Reem D. Mahmood, Alexander D. Murphy, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Chelsey Wheeler, Emma Buckley, Joanna Truelove, Georgia King, Yasmina Ainaoui, Sanjeev S. Bhaskar, Joseph Shaw, D. Gareth R. Evans, Bedirhan Kilerci, Simon P. Pearce, Gerard Brady, Caroline Dive, James P.B. O'Connor, Andrew J. Wallace, Dominic G. Rothwell, Richard J. Edmondson, Gordon C. Jayson
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown.
Autor:
Andrew R Clamp, Elizabeth C James, Iain A McNeish, Andrew Dean, Jae-Won Kim, Dearbhaile M O'Donnell, Dolores Gallardo-Rincon, Sarah Blagden, James Brenton, Tim J Perren, Sudha Sundar, Rosemary Lord, Graham Dark, Marcia Hall, Susana Banerjee, Rosalind M Glasspool, C Louise Hanna, Sarah Williams, Kate M Scatchard, Helena Nam, Sharadah Essapen, Christine Parkinson, Lucy McAvan, Ann Marie Swart, Babasola Popoola, Francesca Schiavone, Jonathan Badrock, Fuad Fananapazir, Adrian D Cook, Mahesh Parmar, Richard Kaplan, Jonathan A Ledermann
Publikováno v:
The Lancet Oncology. 23:919-930
BACKGROUND: Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free and overall survival with dose-
Autor:
Robert D Morgan, Andrew R Clamp, Bethany M Barnes, Kirsten Timms, Helene Schlecht, Laura Yarram-Smith, Yvonne Wallis, Mikel Valganon-Petrizan, Suzanne MacMahon, Rhian White, Sian Morgan, Sarah McKenna, Emma Hudson, Laura Tookman, Angela George, Ranjit Manchanda, Sudha S Sundar, Shibani Nicum, James D Brenton, Rebecca S Kristeleit, Susana Banerjee, Iain A McNeish, Jonathan A Ledermann, Stephen S Taylor, D Gareth R Evans, Gordon C Jayson
Publikováno v:
Morgan, R D, Clamp, A R, Barnes, B M, Timms, K, Schlecht, H, Yarram-Smith, L, Wallis, Y, Valganon-Petrizan, M, Macmahon, S, White, R, Morgan, S, Mckenna, S, Hudson, E, Tookman, L, George, A, Manchanda, R, Sundar, S S, Nicum, S, Brenton, J D, Kristeleit, R S, Banerjee, S, Mcneish, I A, Ledermann, J A, Taylor, S S, Evans, D G & Jayson, G C 2023, ' Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study ', International Journal of Gynecological Cancer . https://doi.org/10.1136/ijgc-2022-004211
ObjectiveOlaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the first year of routine homologo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb793cc9d756983a33fbb917e7372e8
https://doi.org/10.1136/ijgc-2022-004211
https://doi.org/10.1136/ijgc-2022-004211
Autor:
Gordon C. Jayson, Richard J. Edmondson, Dominic G. Rothwell, Andrew J. Wallace, James P.B. O'Connor, Caroline Dive, Gerard Brady, Simon P. Pearce, Bedirhan Kilerci, D. Gareth R. Evans, Joseph Shaw, Sanjeev S. Bhaskar, Yasmina Ainaoui, Georgia King, Joanna Truelove, Emma Buckley, Chelsey Wheeler, Zena Salih, Claire L. Mitchell, Jurjees Hasan, Alexander D. Murphy, Reem D. Mahmood, W. David J. Ryder, George J. Burghel, Marcus Price, Daniel J. White, Andrew R. Clamp, Robert D. Morgan
BRCA2 reversion mutation detected in cell-free circulating DNA from patient 16.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d8190683682e17f23bf7a91a183e796
https://doi.org/10.1158/1078-0432.22490383.v1
https://doi.org/10.1158/1078-0432.22490383.v1
Autor:
Gordon C. Jayson, Richard J. Edmondson, Dominic G. Rothwell, Andrew J. Wallace, James P.B. O'Connor, Caroline Dive, Gerard Brady, Simon P. Pearce, Bedirhan Kilerci, D. Gareth R. Evans, Joseph Shaw, Sanjeev S. Bhaskar, Yasmina Ainaoui, Georgia King, Joanna Truelove, Emma Buckley, Chelsey Wheeler, Zena Salih, Claire L. Mitchell, Jurjees Hasan, Alexander D. Murphy, Reem D. Mahmood, W. David J. Ryder, George J. Burghel, Marcus Price, Daniel J. White, Andrew R. Clamp, Robert D. Morgan
Purpose:A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of PARPi was unknown.P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383a4bd467a2e8ab9634c5efb3f01674
https://doi.org/10.1158/1078-0432.c.6533146
https://doi.org/10.1158/1078-0432.c.6533146
Autor:
Gordon C. Jayson, Richard J. Edmondson, Dominic G. Rothwell, Andrew J. Wallace, James P.B. O'Connor, Caroline Dive, Gerard Brady, Simon P. Pearce, Bedirhan Kilerci, D. Gareth R. Evans, Joseph Shaw, Sanjeev S. Bhaskar, Yasmina Ainaoui, Georgia King, Joanna Truelove, Emma Buckley, Chelsey Wheeler, Zena Salih, Claire L. Mitchell, Jurjees Hasan, Alexander D. Murphy, Reem D. Mahmood, W. David J. Ryder, George J. Burghel, Marcus Price, Daniel J. White, Andrew R. Clamp, Robert D. Morgan
Supplementary Methodology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ac4b273d975d5742c671ed36cc435ae
https://doi.org/10.1158/1078-0432.22490380
https://doi.org/10.1158/1078-0432.22490380